Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation